Express Mail No. EV405281255US

INFORMATION DISCLOSURE STATEMENT		
	Attorney Docket	UCSF-085CON5
	First Named Inventor	NADEL, JAY A.
	Application Number	To Be Assigned
	Confirmation No.	To Be Assigned
	Filing Date	March 31, 2004
Address to: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Group Art Unit	To Be Assigned
	Examiner Name	To Be Assigned
	Title: "PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS"	

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application serial number 09/616,223 filed 7/14/2000 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCSF-085CON5 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: March 31, 2004

By: _____
Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) *(Use several sheets if necessary)*	ATTY. DOCKET NO. UCSF-085 CIP	SERIAL NO. 09/616,223
	APPLICANT Nadel et al.	
	FILING DATE July 14, 2000	GROUP Unassigned

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AN	5,525,625	06/11/96	Bridges et al.			
	AO	6,037,361	03/14/00	Roth et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AP	WO 97/19065	05/29/97	PCT				
	AQ	WO 97/45412	12/04/97	PCT				
	AR	WO 98/37881	09/03/98	PCT				
	AS	WO 99/01421	01/14/99	PCT				
	AT	WO 99/01426	01/14/99	PCT				
	AU	WO 99/32121	07/01/99	PCT				
	AV	WO 00/06560	02/10/00	PCT				
	AW	WO 00/06561	02/10/00	PCT				
	AX	WO 00/09485	02/24/00	PCT				
	AY	WO 00/17162	03/30/00	PCT				

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AA	Donato et al (1989), "Tumor Necrosis Factor Modulates Epidermal Growth Factor Receptor Phosphorylation and Kinase Activity in Human Tumor Cells", *The Journal of Biological Chemistry,* Vol. 264(34): 20474-20481.
	AB	Desseyn et al. (1997), "Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat", *The Journal of Biological Chemistry,* Vol. 272(6): 3168-3178.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) *(Use several sheets if necessary)*	ATTY. DOCKET NO. UCSF-085 CIP	SERIAL NO. 09/616,223
	APPLICANT Nadel et al.	
	FILING DATE July 14, 2000	GROUP Unassigned

	AC	Goldstein et al. (1995), "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model", *Clinical Cancer Research,* Vol. 1: 1311-1318.
	AD	Kawamoto et al. (1983), "Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors fo epidermal growth factor by an anti-receptor monoclonal antibody", *Proc. Natl. Acad. Sci. USA,* Vol. 80: 1337-1341.
	AE	Kondapaka et al. (1996), "Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer", *Molecular and Cellular Endocrinology,* Vol. 117: 53-58.
	AF	Levitski (1994), "Signal-transduction therapy, a novel approach to disease management", *Eur. J. Biochem.,* Vol. 226(1):1-13.
	AG	Lorimer, et al. (1995), "Immunotoxins that Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors", *Clinical Cancer Research,* Vol. 1: 859-864.
	AH	Petit er al. (1997), "Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2/*neu* Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells *in Vitro* and *in Vivo*", *American Journal of Pathology,* Vol. 151(6): 1523-1530.
	AI	Powis (1994), "Signaling pathways as targets for anticancer drug development", *Pharmac. Ther.,* Vol. 62:57-95.
	AJ	Schmidt et al. (1996), "Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα", *British Journal of Cancer,* Vol. 74: 853-862
	AK	Takeyama et al. (1998), "Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules", *Am. J. Physiol.,* Vol. 275:294-302.
	AL	Temann et al. (1997), "A Novel Role for Murine IL-4 *In Vivo*: Induction of MUC5AC Gene Expression and Mucin Hypersecretion", *Am J. Respir. Cell Biol.,* Vol. 16:471-478.
	AM	Ullrich et al. (1984), "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells." *Nature,* Vol. 309(5967):418-25.
	AZ	Brown (1999), "Clinical Studies with matrix metallproteinase inhibitors." *APMIS,* Vol. 107:174-180.
	BA	Grandis, jr., et al. (1997), "Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not norml mucosal epithelial cells." *Oncogene,* Vol. 15(4):409-416.
	BB	Kumar et al. (1998), "Cooperative interaction of autocrine and paracrine mitogens for airway epithelial cells." *Cell Biology and Toxicology,* Vol. 14(4):293-299.
	BC	Lee et al. (2000), "Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals." *American Journal of Respiratory and Critical Care Medicine,* Vol. 161(6):1881-1886.
	BD	Prenzel et al. (1999), "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF." *Nature,* Vol. 402:884-888.
	BE	Takeyama et al. (1999), "Epidermal growth factor system regulates mucin production in airways." *Proceedings of the national Academy of Sciences USA,* Vol. 96(6):3081-3086.
	BF	Takeyama et al. (2000), "Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils." *Journal of Immunology,* Vol. 164(3):1546-1552.
	BG	Wojtowicz-Praga et al. (1997), "Matrix metalloproteinase inhibitors." *Investigational New Drugs."* Vol. 15:61-75.

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) *(Use several sheets if necessary)*	ATTY. DOCKET NO. UCSF-085CIP	SERIAL NO. 09/616,223
	APPLICANT Nadel, et al.	
	FILING DATE July 14, 2000	GROUP Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AA	Grandis et al. (July 24, 1997), "Inhibition of Epidermal Growth Factor Receptor Gene Expression and Function Decreases Proliferation of Head and Neck Squamos Carcinoma but not Normal Mucosal Epithelial Cells." *Oncogene*, Vol. 15(4):406-416.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this bc [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/616,223
				Filing Date	July 14, 2000
				First Named Inventor	Nadel, et al.
				Group Art Unit	1614
(use as many sheets as necessary)				Examiner Name	Zara, Jane
Sheet	1	of	1	Attorney Docket Number	UCSF-085CIP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Documents Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		—				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Documents Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
			—					

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		GUZMAN, et al. "Epidermal growth factor regulates expression of the mucous phenotype of rat tracheal epithelial cells", *Biochem. Biophys. Res. Com.*, (1995) Vol. 217(2): 412-418.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/616,223
Filing Date	July 14, 2000
First Named Inventor	NADEL, JAY A.
Art Unit	1635
Examiner Name	ZARA, JANE
Attorney Docket Number	UCSF-085CIP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5,559,111 (HU P9501230A)		09-24-1996	Guschke	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]–Number[4]–Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) *(Use several sheets if necessary)*	ATTY. DOCKET NO. UCSF085CIP	SERIAL NO. 09/616,223
	APPLICANT Nadel et al.	
	FILING DATE July 14, 2000	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AA	WO 00/10588 A3	03/02/2000	PCT				

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

F:\DOCUMENT\UCSF\085cip\Supp.Form PTO-1449.doc

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Notice of References Cited	Application/Control No. 09/616,223	Applicant(s)/Patent Under Reexamination NADEL ET AL.	
	Examiner Jane Zara	Art Unit 1635	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-,306,874 B1	10-2001	Fraley et al.	514/300
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Giorgio Palu' et al., In pursuit of new developments for gene therapy of human diseases, JOURNAL OF BIOTECHNOLOGY, 68 (1991) pp. 1-13
	V	Stanley T. Crooke, Antisense Research and Application, pp. 1-50
	W	Andrea D. Branch, A good antisense molecule is hard to find, TIBS 23 - February 1998, pp. 45-50
	X	Karen Pihl-Carey, Isis To Crohn's Disease Drug Fails In Phase III, BIOWORLD TODAY, Vol. 10, No. 239, pp. 1-2

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited	Application/Control No. 09/616,223	Applicant(s)/Patent Under Reexamination NADEL ET AL.	
	Examiner Jane Zara	Art Unit 1635	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-,306,874 B1	10-2001	Fraley et al.	514/300
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Giorgio Palu' et al., In pursuit of new developments for gene therapy of human diseases, JOURNAL OF BIOTECHNOLOGY, 68 (1991) pp. 1-13
	V	Stanley T. Crooke, Antisense Research and Application, pp. 1-50
	W	Andrea D. Branch, A good antisense molecule is hard to find, TIBS 23 - February 1998, pp. 45-50
	X	Karen Pihl-Carey, Isis To Crohn's Disease Drug Fails In Phase III, BIOWORLD TODAY, Vol. 10, No. 239, pp. 1-2

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

App

Notice of References Cited	Application/Control No. 09/616,223	Applicant(s)/Patent Under Reexam Nadel et al	
	Examiner Jane Zara	Art Unit 1635	Page 1 of 1

U.S. PATENT DOCUMENTS

		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Name	Classification[2]	
	A					
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Country	Name	Classification[2]	
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS

		Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	U	Masui et al. Cancer Res. 1984 Vol. 44, pp. 1002-1007.
	V	Yoneda et al. Cancer Res. 1991. Vol. 51, pp. 4430-4435.
	W	Khetarpal et al. Drug Metabolism and Disposition. 1994. Vol. 22, No. 2, pp. 216-223.
	X	Buchdunger et al. Proc. Natl. Acad. Sci. USA 1994 Vol. 91, pp. 2334-2338.

* A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a). [1] Dates in MM-YYYY format are publication dates. [2] Classifications may be U.S. or foreign.